BPC-157 (Body Protection Compound 157)
PeptideThe substantial divergence (medical: 22, community: 78) is explained by the fact that the medical assessment considers only controlled human data, which are virtually absent for BPC-157 [s2, s3], whereas community reports are based on uncontrolled self-experimentation in which placebo effects, spontaneous recovery, and selection bias cannot be excluded [c1, c2, c3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
BPC-157 shows impressive healing effects in animal and in-vitro studies, but as of 2026 not a single placebo-controlled trial in humans exists — only case series of 12 people each. Community reports on tendon and gut issues are numerous and mostly positive, but without control groups and with uncontrolled product quality, they're hard to interpret. The theoretical cancer risk from angiogenesis promotion is a mechanistically grounded safety signal, not a disclaimer to ignore. Anyone using BPC-157 is operating in a regulatory grey zone and should weigh the risk-benefit ratio soberly.
Description
Synthetic 15-amino acid peptide derived from gastric juice protein that promotes tissue healing, angiogenesis, and organ protection in animal models. Clinical evidence in humans remains very limited [s1, s2].
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It consists of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val [s3]. First described in 1993 by Predrag Sikiric, it has since been investigated in numerous preclinical rodent studies [s1]. In animal models, BPC-157 demonstrates a broad regenerative activity spectrum: healing of tendons, ligaments, muscles, nerves, and bone, as well as protection of gastrointestinal mucosa, liver, and pancreas [s1, s4, s5]. The peptide is stable in gastric acid and can be administered orally, subcutaneously, or intramuscularly [s6, s7]. Clinical human studies are extremely limited: a systematic review identified only a single human study (a 12-subject case series without a control group or blinding) for orthopedic indications [s2]. Additional small pilot studies on interstitial cystitis (n=12) and knee pain (n=16) are available [s8]. A Phase I study (NCT02637284, n=42) was initiated in 2016 but terminated prematurely without publication of results [s16]. In the biohacker community, BPC-157 is primarily used for tendon injuries, joint pain, and gastrointestinal issues. As of the current state of evidence (2026), scientific support for human use remains very low [s3, s2].
Legal Status (DE)
Not approved as a medicinal product in Germany, Austria, or Switzerland (no BfArM/EMA/Swissmedic authorization). Not an approved dietary supplement. Distribution as a research chemical constitutes a legal grey area; sale as a medicinal product or dietary supplement is not legal in the EU. Not listed under the Anti-Doping Act (AntiDopG), but included on the WADA Prohibited List (Class S0: Non-approved substances) [s13, s14, s15, s16].
Mechanism of Action
BPC-157 acts through multiple molecular signaling pathways simultaneously [s1, s4]: 1. Angiogenesis: BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) at the mRNA and protein level in endothelial cells without increasing VEGF-A itself. This leads to activation of the Akt-eNOS signaling pathway and enhanced nitric oxide (NO) production, promoting new blood vessel formation [s1, s4]. 2. Growth hormone receptor modulation: In tendon fibroblasts, BPC-157 upregulates the growth hormone receptor (GHR) at the mRNA and protein level and potentiates downstream JAK2 signaling in response to GH. This accounts for the observed effects on tendon healing [s4, s7]. 3. NO system: BPC-157 modulates the nitric oxide system in both a stimulatory manner (via eNOS activation) and an inhibitory manner (during NO overproduction), which may explain its cytoprotective effects on gastrointestinal mucosa and tissues [s1, s5]. 4. Cell migration and extracellular matrix: The peptide influences tenoblast migration and supports extracellular matrix organization, promoting outgrowth of tendon cells from tissue explants in animal studies without inducing uncontrolled cell proliferation [s4, s9]. 5. Cytokine modulation: BPC-157 reduces pro-inflammatory cytokines and modulates multiple signaling pathways involved in cell growth and angiogenesis [s10]. 6. Gut-brain axis: BPC-157 acts as a potential mediator of the gut-brain axis, influences dopaminergic and serotonergic systems, and exhibits neuroprotective properties in animal models [s11].
Dosing
Sehnenheilung / muskuloskelettale Verletzung (subkutan/intramuskulär)
- Dose
- 200–500 mcg per dose (research reference: 2.5–3.75 mcg/kg)
- Frequency
- 1-2× täglich
- Route
- injektion-subkutan
- Duration
- 4-8 Wochen
- Timing
- Morning and/or evening, fasted or with a meal
- With food
- optional
Gastrointestinale Probleme (oral)
- Dose
- 250–500 mcg per dose
- Frequency
- 2× täglich
- Route
- oral
- Duration
- 4-8 Wochen
- Timing
- On an empty stomach, 30 minutes before eating
- With food
- vermeiden
Intravenöse Anwendung (nur Forschungskontext)
- Dose
- Up to 20 mg IV was tolerated in a safety study with 2 subjects
- Frequency
- Einmalig (Forschung)
- Route
- oral
- Duration
- Einmalig
- Timing
- Under medical supervision only
- With food
- optional
No officially established upper limit in humans. No lethal dose (LD50) has been determined in animal studies [s7]. An IV safety study (n=2) tolerated doses up to 20 mg without adverse effects [s12]. Higher doses in humans have not been adequately investigated.
All dosing information is based on preclinical animal studies or small uncontrolled human self-reports. No evidence-based dosing recommendations exist for humans. BPC-157 is not an approved medicinal product [s2, s3, s13].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Reaktion an der Injektionsstelle (Rötung, Schwellung, Kribbeln, Wärme) Most frequently reported adverse effect in user reports and small pilot studies with subcutaneous or intramuscular injection [s8, s16]. | gelegentlich | leicht |
| Übelkeit oder leichte gastrointestinale Beschwerden Occasionally reported with oral administration; no severe GI events documented in small pilot studies [s8]. | selten | leicht |
| Theoretisches Tumorwachstums-Risiko durch Angiogenese-Förderung BPC-157 promotes neovascularization (angiogenesis) via VEGFR2 activation. Theoretically, this mechanism could favor growth of existing or subclinical tumors. No documented case report, but mechanistically plausible [s1, s4, s16]. | theoretisch | schwer |
| Blutdruckveränderungen durch NO-Modulation As BPC-157 modulates the NO system, theoretical effects on vascular tone and blood pressure are possible; no human data available to date [s1]. | theoretisch | moderat |
Contraindications
The angiogenic mechanism of action (VEGFR2 activation) could theoretically promote tumor vascularization and growth. Due to the absence of human safety data, use in cancer patients must be strictly avoided [s1, s4].
No safety data available for pregnant or breastfeeding women. Given the effects on angiogenesis and tissue development, use is contraindicated [s2, s3].
Absence of human pharmacokinetic data; accumulation and unpredictable effects due to impaired organ clearance cannot be excluded [s7].
NO modulation can affect platelet function and vascular tone; interactions with anticoagulants are theoretically possible [s1].
Interactions
Synergistic
Frequently combined in the biohacker community; TB-500 acts via actin polymerization and cell migration, BPC-157 via VEGFR2 and the NO system. Synergism is theoretically plausible, but no controlled human data exist [s17].
BPC-157 is frequently combined with ipamorelin to support tissue healing and joint health. Ipamorelin promotes pulsatile growth hormone secretion, while BPC-157 stimulates local repair processes.
The combination of BPC-157 with CJC-1295 is used in the biohacker community for enhanced regeneration and anabolic effects. CJC-1295 sustainably stimulates GH and IGF-1, while BPC-157 accelerates healing processes.
GHK-Cu and BPC-157 act synergistically on wound healing and collagen synthesis. GHK-Cu stimulates collagen and elastin production, while BPC-157 promotes angiogenesis and tissue regeneration.
Caution
Theoretical interaction via the NO system and possible effect on platelet function; bleeding risk cannot be excluded [s1].
NO-modulating activity of BPC-157 may potentiate or attenuate the antihypertensive effect of antihypertensive agents [s1].
BPC-157 modulates inflammatory pathways and cytokines; potential interactions with immunosuppressants cannot be excluded [s10].
BPC-157 can counteract NSAID-induced gastric mucosal damage via COX-independent mechanisms. This interaction is potentially beneficial for the gastrointestinal tract; however, the full interaction at the inflammatory level is complex and not yet fully elucidated.
Studies
Tier B — Moderate Evidence
Outcome: Identification of all human and preclinical studies on musculoskeletal applications of BPC-157; only 1 human study found (12-patient case series).
Effect Size: 7 of 12 patients with chronic knee pain reported relief for 6+ months after a single BPC-157 injection (no control group).
Outcome: 36 studies from 1993–2025 included; BPC-157 increases GHR expression and modulates angiogenic/inflammatory pathways.
Effect Size: Qualitative summary; no pooled effect sizes.
Tier C — Low Evidence
Outcome: Interstitial cystitis (n=12): 80–100% symptom relief with intravesical injection. Knee pain (n=16): 87.5% reported significant relief. IV safety (n=2): 20 mg IV tolerated without adverse effects.
Effect Size: No control groups; results not adjusted for confounding. Evidence level very low.
Outcome: IV infusion of BPC-157 up to 20 mg tolerated in 2 adult subjects without reported adverse effects.
Effect Size: No efficacy endpoints; pure safety observation.
Outcome: BPC-157 accelerates outgrowth of tendon cells in vitro and Achilles tendon healing in rat model; no effect on healthy cell proliferation.
Effect Size: Significant effects in preclinical models; not transferable to humans.
Community Evidence
Top reported benefits
- Faster recovery from tendon injuries (elbow, knee, shoulder)
- Reduction of chronic joint pain
- Improvement in gastrointestinal complaints (IBS, leaky gut)
- General sense of recovery and resilience following injuries
Top reported issues
- Unclear product quality / lack of quality control of research peptides
- Injection site reactions (redness, tingling)
- No noticeable effect in some users
- High cost for an unapproved research product
Several users and German specialist sources highlight the theoretical cancer risk associated with angiogenesis promotion [c4, s16]. The lack of regulatory quality control over product quality is a recurring concern. Many positive reports come from users who simultaneously underwent physiotherapy or other interventions, making causal attribution impossible [c1, c2, c3].
Scientific Sources
- BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Role in Tissue Healing
Sikiric P, et al. (2025). PubMed Central / PMCBLink - S808 Oral Peptide BPC-157 – An Emerging Adjunct (Systematic Review Abstract)
American College of Gastroenterology (2025). American Journal of GastroenterologyCLink - The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
Vukojevic J, Milavic M, Perovic D, et al. (2020). Brain and BehaviorBDOI - Safety of Intravenous Infusion of BPC157 in Humans
Unbekannte Autoren (PubMed-Eintrag) (2025). PubMedCPMID:40131143 - BPC-157 FDA Approval Status 2026 and RFK Reclassification
AgeMD Redaktion (2026). agemd.comDLink - BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products
Operation Supplement Safety (OPSS) (2024). opss.org / HHSBLink - Peptide, Abnehmspritzen & Co.: Grauzone oder Strafbarkeit? (Rechtstipp)
anwalt.de Redaktion (2024). anwalt.deCLink - BPC-157 im Bodybuilding: Wirkung, Risiken und aktuelle Studienlage
REP ONE Redaktion (2025). repone.deCLink - BPC-157 und TB-500: Forschungsmechanismen
Peptide Regeneresis Redaktion (2024). peptideregenesis.comDLink - BPC-157: Wirkung, Studien & Rechtslage 2026
parahealth Redaktion (2026). parahealth.deCLink - Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736)
Sikiric P, Seiwerth S, Rucman R, et al. (2019). Journal of Physiology and Pharmacology / ScienceDirectBLink - Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). PMC / Orthopaedic Journal of Sports MedicineBPMID:40789979DOI - BPC-157 – DocCheck Flexikon Eintrag
DocCheck Medical Services GmbH (2026). DocCheck FlexikonCLink - The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, Tsai WC, Lin MS, et al. (2011). Journal of Applied PhysiologyBDOI - Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Sikiric P, Seiwerth S, Rucman R, et al. (2017). Current Neuropharmacology / PMCBLink - BPC-157 Dosing Guide: Protocol, Reconstitution & Safety (2026)
Peptide Dosing Protocols (Redaktion) (2026). peptidedosingprotocols.comDLink - BPC-157 benefits, dosage, and side effects
Examine.com Redaktion (2024). Examine.comCLink - BPC-157 Human Clinical Trials (2025-2026): Complete Status & Results
Peptide Database Redaktion (2025). peptide-db.comDLink - Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Gwyer D, Bhatt DL, Wilson EV, et al. (2019). Cell and Tissue ResearchBDOI
Community Sources
Storage
Unopened
Store lyophilized powder frozen at -20°C, protected from light.
Opened
After reconstitution with bacteriostatic water, store at 2–8°C (refrigerator); use within 30 days. Do not freeze after reconstitution.
Notes
BPC-157 is stable as a lyophilized powder. More stable in gastric acid than most peptides, enabling oral bioavailability [s5, s6]. Quality verification by independent third-party analysis (HPLC, mass spectrometry) is recommended for research peptides, as no regulatory quality control exists.